- Home
- AUST vs TXMD Comparison
AUST vs TXMD Comparison
Compare AUST & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AUST | TXMD |
|---|---|---|
| Founded | 2020 | 2008 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.3M | 25.9M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | AUST | TXMD |
|---|---|---|
| Price | $1.72 | $2.35 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 3.9M | 98.0K |
| Earning Date | 02-26-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.03 |
| Revenue | N/A | ★ $2,796,000.00 |
| Revenue This Year | N/A | $427.09 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $90.45 |
| Revenue Growth | N/A | ★ 75.19 |
| 52 Week Low | $1.05 | $0.72 |
| 52 Week High | $3.92 | $2.95 |
Technical Indicators
Market Signals| Indicator | AUST | TXMD |
|---|---|---|
| Relative Strength Index (RSI) | 44.40 | 51.83 |
| Support Level | $1.65 | $2.12 |
| Resistance Level | $2.15 | $2.51 |
| Average True Range (ATR) | 0.35 | 0.21 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 6.04 | 47.85 |
Price Performance
Historical ComparisonAbout AUST Austin Gold Corp.
Austin Gold Corp is focused on the acquisition, exploration and evaluation of mineral resource properties in the western United States of America (USA). Exploration and development of mineral projects is considered the Company's single business segment. Its projects include Kelly Creek in Humboldt County, Lone Mountain and Miller in Elko County, and Stockade Mountain (Oregon).
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.